What is Q32 Bio's market cap?

Q32 Bio (QTTB) has a market capitalization of $451.9M and trades on NASDAQ.

Who are Q32 Bio's competitors?

Q32 Bio's key competitors include Eli Lilly and Company, Pfizer Inc., Incyte Corporation, and others. These companies compete in similar markets and product categories.

Who does Q32 Bio partner with?

Q32 Bio's notable partners include Bristol-Myers Squibb Company, Akebia Therapeutics, Inc., Amgen Inc., and others.

What subsidiaries does Q32 Bio have?

Q32 Bio's subsidiaries include Q32 Bio Operations Inc..

Where is Q32 Bio headquartered?

Q32 Bio is headquartered in United States of America and employs approximately 39 people. It has been publicly traded since 2024.

Q32 Bio

QTTB

Q32 Bio Inc. is a clinical-stage biotechnology company dedicated to developing novel biologics that restore immune balance in patients with autoimmune and inflammatory diseases.

Market cap

$451.87M+1,690%

Table of contents

Earnings

Q1 2026 report

May 5, 2026

EPS-$0.54Miss by $0.02

Read the full report

Next report

Aug 5, 2026 (In 1 week)

Revenue estimate$1.0M

EPS estimate-$0.53

Competitors

By market cap

Eli Lilly$1.07T+47.2%

Pfizer$140.61B+1.7%

Incyte$23.7B+74.9%

Cullinan Therapeutics, Inc.$1.1B+121%

Avalo Therapeutics$1.0B+1,348%

Q32 Bio$451.9M+1,561%

Indaptus Therapeutics, Inc.$271.8M+4,490%

SAB Biotherapeutics$263.0M+1,019%

By revenue growth

Eli Lilly+47.4%

Incyte+26.9%

Pfizer+1.4%

By net margin

Eli Lilly34.99%+12.3pp

Incyte27.71%+8.7pp

Pfizer15.65%+6.3pp

Cullinan Therapeutics, Inc.-346.14%—

Avalo Therapeutics-7,965.76%—

Profile

Q32 Bio Inc. is a clinical-stage biotechnology company dedicated to developing novel biologics that restore immune balance in patients with autoimmune and inflammatory diseases. The company's primary focus is on re-regulating adaptive immune function and tissue-targeted complement inhibition to treat conditions driven by pathological immune dysfunction. Its lead programs target severe dermatological and systemic immune disorders through potent cytokine signaling blockade.

Competitive position

A clinical-stage innovator in the IL-7Rα space with a proprietary tissue-targeted complement platform and strategic licensing agreements with major pharmaceutical entities.

GeographiesUnited States, Global

Customer segmentsPatients, Pharmaceutical Companies

Business modelDrug Development, IP Licensing

SuppliersContract Manufacturing Organizations (CMOs), Academic Research Institutions, Clinical Research Organizations (CROs)

CustomersSpecialty Pharmacies, Hospitals, Biotechnology Licensees

CountryUnited States of America

Listed2024

Employees39.0

CEOJodie Pope Morrison

SectorHealthcare

IndustryBiotechnology

Websiteq32bio.com

FilingsSEC EDGAR

Questions, answered.

What is Q32 Bio's market cap?: Q32 Bio (QTTB) has a market capitalization of $451.9M and trades on NASDAQ.
Who are Q32 Bio's competitors?: Q32 Bio's key competitors include Eli Lilly and Company, Pfizer Inc., Incyte Corporation, and others. These companies compete in similar markets and product categories.
Who does Q32 Bio partner with?: Q32 Bio's notable partners include Bristol-Myers Squibb Company, Akebia Therapeutics, Inc., Amgen Inc., and others.
What subsidiaries does Q32 Bio have?: Q32 Bio's subsidiaries include Q32 Bio Operations Inc..
Where is Q32 Bio headquartered?: Q32 Bio is headquartered in United States of America and employs approximately 39 people. It has been publicly traded since 2024.